

July 26, 2019

BSE Limited

Floor 25, P. J. Towers
Dalal Street, Fort
Mumbai - 400 001

National Stock Exchange of India Limited

Exchange Plaza
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sirs,

Subject: Evaluate options to create focused entities for JLL businesses

The board of directors of the Company (“Board”) at its meeting held on July 26, 2019 considered the option of reorganizing its businesses with the following objectives:

- (a) create separate and focused entities for Pharmaceuticals and Life Science Ingredients businesses to manage different risks, rewards and regulatory requirements;
- (b) enable strategic growth for these businesses with optimal capital structure;
- (c) potentially unlock shareholder value with direct ownership in each of the business entities.

The Board has constituted a Committee to evaluate various options including reorganisation / demerger of business undertakings on a going concern basis and provide its recommendations. Any decision in this regard will be after due evaluation and consideration by the Board and be subject to all necessary consents and approvals.

The Company will at the relevant time take necessary steps to comply with all applicable laws and regulations including the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

This is for information and record.

Thanking you,

Yours faithfully,

For Jubilant Life Sciences Limited

Rajiv Shah
Company Secretary

A Jubilant Bhartia Company

OUR VALUES



Jubilant Life Sciences Limited

1-A, Sector 16-A,
Noida-201 301, UP, India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP, India
CIN : L24116UP1978PLC004624